In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies

Journal of Infectious Diseases

Volumn 173, Issue 6, 1996, Pages 1379-1387

  Jacobsen, Helmut ^a   Hänggi, Markus ^b   Ott, Michael ^b   Duncan, Lan B ^b   Owen, Samantha ^b   Andreoni, Massimo ^b   Vella, Stefano ^b   Mous, Jan ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCINE; LEUCINE; METHIONINE; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; VALINE; VIRUS DNA; VIRUS ENZYME; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROVIRUS; RANDOMIZED CONTROLLED TRIAL; VIRUS MUTANT; VIRUS TYPING;

EID: 0029824426     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.6.1379     Document Type: Article

References (15)

1. Dickson C, Eisenman R, Fan H, Hunter E, Teich N. Protein biosynthesis and assembly. 2nd ed. In: Weiss R, Teich N, Varmus H, Coffin J, eds. RNA tumor viruses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1984;513-648.
2. Kräusstich HG, Wimmer E. Viral proteinases. Annu Rev Biochem 1988; 57:701-54.
3. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85:4686-90.
4. Le Grice SFJ, Mills J, Mous J. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. EMBO J 1988; 7:2547-53.
5. Mous J, Heimer EP, Le Grice SFJ. Processing protease and reverse transcriptase from HIV-1 polyprotein in Escherichia coli. J Virol 1988; 62: 1433-6.
6. Seelmeier S, Schmidt H, Turk V, von der Helm K. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci USA 1988;85:6612-6.
7. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci USA 1990;87:7472-6.
8. Dreyer GB, Metcalf BW, Tomaszek TA Jr, et al. Inhibition of human immunodeficiency virus 1 protease in vitro: Rational design of substrate analogue inhibitors. Proc Natl Acad Sci USA 1989;86:9752-6.
9. 2 symmetric inhibitors of the human immunodeficiency virus type I protease. Antimicrob Agents Chemother 1991;35:220914.
10. Lam PYS, Jadhav PK, Eyermann CJ, et al. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994;263:380-4.
11. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994;91:4096-100.
12. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JD. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991; 16:295-305.
13. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990;248:358-61.
14. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-5.
15. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-8.